Vyrsa Technologies has an array of SI joint devices and was founded in 2021. It’s the only SI joint company with a complete portfolio of FDA-cleared sacroiliac joint fusion implants.
The deal was completed Nov. 30 and values Vyrsa at $40 million. Nevro will also pay up to an additional $35 million pending development and sales milestones.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
